State Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Xiang'an Hospital, School of Medicine, Xiamen University, Xiamen, 361102, China.
Xiamen Key Laboratory for TCM Dampness Disease, Neurology & Immunology Research, Department of Traditional Chinese Medicine, Xiang'an Hospital, School of Medicine, Xiamen University, Xiamen, 361102, China.
Acta Pharmacol Sin. 2023 Nov;44(11):2151-2168. doi: 10.1038/s41401-023-01125-3. Epub 2023 Jul 7.
Alzheimer's disease (AD) is a neurodegenerative disease with subtle onset, early diagnosis remains challenging. Accumulating evidence suggests that the emergence of retinal damage in AD precedes cognitive impairment, and may serve as a critical indicator for early diagnosis and disease progression. Salvianolic acid B (Sal B), a bioactive compound isolated from the traditional Chinese medicinal herb Salvia miltiorrhiza, has been shown promise in treating neurodegenerative diseases, such as AD and Parkinson's disease. In this study we investigated the therapeutic effects of Sal B on retinopathy in early-stage AD. One-month-old transgenic mice carrying five familial AD mutations (5×FAD) were treated with Sal B (20 mg·kg·d, i.g.) for 3 months. At the end of treatment, retinal function and structure were assessed, cognitive function was evaluated in Morris water maze test. We showed that 4-month-old 5×FAD mice displayed distinct structural and functional deficits in the retinas, which were significantly ameliorated by Sal B treatment. In contrast, untreated, 4-month-old 5×FAD mice did not exhibit cognitive impairment compared to wild-type mice. In SH-SY5Y-APP cells, we demonstrated that Sal B (10 μM) significantly decreased BACE1 expression and sorting into the Golgi apparatus, thereby reducing Aβ generation by inhibiting the β-cleavage of APP. Moreover, we found that Sal B effectively attenuated microglial activation and the associated inflammatory cytokine release induced by Aβ plaque deposition in the retinas of 5×FAD mice. Taken together, our results demonstrate that functional impairments in the retina occur before cognitive decline, suggesting that the retina is a valuable reference for early diagnosis of AD. Sal B ameliorates retinal deficits by regulating APP processing and Aβ generation in early AD, which is a potential therapeutic intervention for early AD treatment.
阿尔茨海默病(AD)是一种起病隐匿的神经退行性疾病,早期诊断仍然具有挑战性。越来越多的证据表明,AD 患者的视网膜损伤先于认知障碍出现,可能成为早期诊断和疾病进展的重要指标。丹参素 B(Sal B)是一种从传统中药丹参中分离得到的生物活性化合物,已被证明对治疗 AD 和帕金森病等神经退行性疾病具有潜力。在本研究中,我们研究了 Sal B 对早期 AD 视网膜病变的治疗作用。我们用 Sal B(20mg·kg·d,灌胃)治疗携带 5 种家族性 AD 突变的 1 个月大转基因小鼠(5×FAD)3 个月。治疗结束时,评估视网膜功能和结构,在 Morris 水迷宫测试中评估认知功能。我们发现,4 个月大的 5×FAD 小鼠的视网膜表现出明显的结构和功能缺陷,Sal B 治疗显著改善了这些缺陷。相比之下,未经治疗的 4 个月大的 5×FAD 小鼠与野生型小鼠相比,没有表现出认知障碍。在 SH-SY5Y-APP 细胞中,我们证明 Sal B(10μM)可显著降低 BACE1 的表达和高尔基体分选,从而通过抑制 APP 的β裂解减少 Aβ生成。此外,我们发现 Sal B 可有效减轻 5×FAD 小鼠视网膜中 Aβ斑块沉积引起的小胶质细胞激活和相关炎症细胞因子释放。总之,我们的结果表明,视网膜的功能损伤先于认知能力下降,提示视网膜是 AD 早期诊断的一个有价值的参考。Sal B 通过调节 APP 处理和早期 AD 中的 Aβ生成改善视网膜缺陷,这是治疗早期 AD 的一种潜在治疗干预措施。